文献速递基础与转化研究组学、生物样本库与精准医学

肽探针检测遗传性淀粉样变性患者血浆中错误折叠的转甲状腺素蛋白寡聚体

Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.
PubMed 文献 · Sci Transl Med · 2017-01-01

研究报道了可选择性标记转甲状腺素蛋白(TTR)遗传性淀粉样变性患者血浆中错误折叠TTR寡聚体的肽探针;这类寡聚体在健康对照、无症状突变携带者及TTR相关心肌病患者中明显更少,且在经疾病修饰治疗(tafamidis或肝移植介导的基因治疗)后减少。

要点

  • 肽探针可选择性检测TTR遗传性淀粉样变性患者血浆中错误折叠的TTR寡聚体。
  • 健康对照、无症状突变携带者及TTR相关心肌病患者血浆中错误折叠TTR寡聚体明显更少。
  • 经tafamidis或肝移植介导的基因治疗后,TTR淀粉样多神经病患者错误折叠寡聚体减少。

核心结论

  • 肽探针可选择性标记TTR遗传性淀粉样变性患者血浆中错误折叠的TTR寡聚体,并可能成为早期诊断策略、治疗反应生物标志物及研究结构-蛋白毒性关系的工具。

研究设计与样本

  • 研究使用基于肽的探针检测血浆中错误折叠的TTR寡聚体,比较了TTR遗传性淀粉样变性患者、健康对照、无症状突变携带者及TTR相关心肌病患者。

主要发现

  • 肽探针在表现为 predominantly 神经病表型的TTR遗传性淀粉样变性患者血浆中选择性标记错误折叠的TTR寡聚体。
  • 健康对照、与淀粉样多神经病相关突变的无症状携带者及TTR相关心肌病患者血浆中错误折叠TTR寡聚体明显更少。
  • 心肌病患者血浆中无错误折叠TTR寡聚体,提示TTR淀粉样变性中的组织趋向性是基于结构的。
  • 接受疾病修饰治疗(tafamidis或肝移植介导的基因治疗)的TTR淀粉样多神经病患者中错误折叠寡聚体减少。
  • 在部分TTR淀粉样多神经病患者中,探针还检测到一种循环TTR片段,该片段在tafamidis治疗后消失。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing evidence supports the hypothesis that soluble misfolded protein assemblies contribute to the degeneration of postmitotic tissue in amyloid diseases. However, there is a dearth of reliable nonantibody-based probes for selectively detecting oligomeric aggregate structures circulating in plasma or deposited in tissues, making it difficult to scrutinize this hypothesis in patients. Hence, understanding the structure-proteotoxicity relationships driving amyloid diseases remains challenging, hampering the development of early diagnostic and novel treatment strategies. We report peptide-based probes that selectively label misfolded transthyretin (TTR) oligomers circulating in the plasma of TTR hereditary amyloidosis patients exhibiting a predominant neuropathic phenotype. These probes revealed that there are much fewer misfolded TTR oligomers in healthy controls, in asymptomatic carriers of mutations linked to amyloid polyneuropathy, and in patients with TTR-associated cardiomyopathies. The absence of misfolded TTR oligomers in the plasma of cardiomyopathy patients suggests that the tissue tropism observed in the TTR amyloidoses is structure-based. Misfolded oligomers decrease in TTR amyloid polyneuropathy patients treated with disease-modifying therapies (tafamidis or liver transplant-mediated gene therapy). In a subset of TTR amyloid polyneuropathy patients, the probes also detected a circulating TTR fragment that disappeared after tafamidis treatment. Proteomic analysis of the isolated TTR oligomers revealed a specific patient-associated signature composed of proteins that likely associate with the circulating TTR oligomers. Quantification of plasma oligomer concentrations using peptide probes could become an early diagnostic strategy, a response-to-therapy biomarker, and a useful tool for understanding structure-proteotoxicity relationships in the TTR amyloidoses.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Schonhoft JD, Monteiro C, Plate L, et al. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. 2017. PMID: 28904227. doi:10.1126/scitranslmed.aam7621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。